Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Brainsway Ltd(BWAY)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for BWAY
10/23/2026: BWAY (3-star) is currently NOT-A-BUY. Pass it for now.
BrainsWay Ltd is a medical device company that specializes in Deep Transcranial Magnetic Stimulation (Deep TMS) to treat mental health disorders such as depression and OCD. The company has a leading position in neurostimulation due to its patented H-Coil technology, which enables deeper brain stimulation compared to standard alternatives. Its investment story centers on the growing adoption of non-invasive therapies and recurring revenue from its installed device base. However, the company faces risks related to healthcare reimbursement policies, intense competition, and high commercialization costs. It may suit growth-oriented investors who are comfortable with the volatility inherent in medical technology and should monitor future FDA clearances and insurance adoption trends.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The company is in an active commercial expansion phase with significant TAM exposure. |
| Momentum investor | Strong fit while signal remains positive | Momentum investors may find opportunity during periods of clinical or commercial acceleration. |
| Value investor | Weak fit | The stock is currently priced for growth rather than traditional value metrics. |
| Dividend investor | Weak fit | The company does not pay a dividend and reinvests all capital. |
| Low-risk investor | Weak fit | High volatility and sensitivity to regulatory and commercial outcomes make this high-risk. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock is subject to significant swings based on clinical updates and quarterly results. |
| Valuation risk | Medium / high | High growth expectations can lead to valuation sensitivity. |
| Competition risk (Neurostimulation technology) | Medium | Advancements by competitors could erode the technological edge of Deep TMS. |
| Business quality | Medium | The company operates a specialized medical device model with good scalability. |
| Dividend income | Low / none | There is no current plan to initiate a dividend. |
| Execution risk | Medium / high | Successful commercialization depends on widespread adoption by independent clinics. |
Price Behavior
Rolling Over
The price momentum is slowing down and beginning to turn downward.
Moderately Choppy
The stock has experienced noticeable price swings while retaining some directional structure.
Analysis of Past Performance
Type Stock | Historic Profit 148.6% | Avg. Invested days 45 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 10/23/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 452.85M USD | Price to earnings Ratio 48.91 | 1Y Target Price 19.27 |
Price to earnings Ratio 48.91 | 1Y Target Price 19.27 | ||
Volume (30-day avg) 103.2K shares | Beta 0.1 | 52 Weeks Range 7.13 - 17.40 | Updated Date 10/24/2026 |
52 Weeks Range 7.13 - 17.40 | Updated Date 10/24/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.23 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Equipment Sales | Selling Deep TMS systems to hospitals and private clinics. | Revenue comes from the hardware sales of the brain stimulation devices. |
| Service and Support | Recurring revenue from service contracts and maintenance. | This provides a steady, recurring income stream after the initial sale. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE 48.91 | Forward PE 46.73 | Enterprise Value 218.93M | Price to Sales(TTM) 7.46 |
Enterprise Value 218.93M | Price to Sales(TTM) 7.46 | ||
Enterprise Value to Revenue 4.75 | Enterprise Value to EBITDA 26.38 | Shares Outstanding 40.25M | Shares Floating 24.11M |
Shares Outstanding 40.25M | Shares Floating 24.11M | ||
Percent Insiders 2.59 | Percent Institutions 29.57 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.